Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.64 |
| ▸ | NPY1R | P25929 | 9/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.64 |
| ▸ | NPY2R | P49146 | 5/20 | 0.64 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434577 | 0.94 | NPY4R (0.72) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30198871 | 0.91 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL35402427 | 0.89 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL17241349 | 0.88 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL17241345 | 0.88 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31174227 | 0.87 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29901565 | 0.87 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL31031618 | 0.87 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31199205 | 0.87 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL8827156 | 0.86 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140490-A1 | APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRIDAE INFECTIONS | Berlin Cures GmbH (DE) | 2023-05-04 | — | — | US | claimed |
| CN-115768895-A | Aptamers for the treatment of infections of the coronavirus family | 柏林制药股份有限公司 | 2023-03-07 | — | — | CN | claimed |
| US-12606828-B2 | Aptamers for use in the treatment of Coronaviridae infections | APTA Therapeutics GmbH (DE) | 2026-04-21 | — | — | US | disclosed |
| EP-4288547-B1 | APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRIDAE INFECTIONS | Berlin Cures GmbH (DE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240191241-A1 | APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRIDAE INFECTIONS | Berlin Cures GmbH (DE) | 2024-06-13 | — | — | US | disclosed |
| CN-117500927-A | Aptamer for treating coronaviridae infection | 柏林制药股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4288547-A1 | APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRIDAE INFECTIONS | Berlin Cures GmbH (DE) | 2023-12-13 | — | — | EP | disclosed |
| US-20230140490-A1 | APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRIDAE INFECTIONS | Berlin Cures GmbH (DE) | 2023-05-04 | — | — | US | disclosed |
| CN-115768895-A | Aptamers for the treatment of infections of the coronavirus family | 柏林制药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4133083-A1 | APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRIDAE INFECTIONS | Berlin Cures GmbH (DE) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022214670-A1 | APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRIDAE INFECTIONS | Berlin Cures GmbH (DE) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606828-B2 | Aptamers for use in the treatment of Coronaviridae infections | DNTT, TPT1, TEKT1 | NPY4R 4244/4885NPY1R 2791/4885NPY5R 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.